WO2006065975A3 - Methods of treating ankylosing spondylitis using anti-tnf antibodies and peptides of human tumor necrosis factor - Google Patents
Methods of treating ankylosing spondylitis using anti-tnf antibodies and peptides of human tumor necrosis factor Download PDFInfo
- Publication number
- WO2006065975A3 WO2006065975A3 PCT/US2005/045388 US2005045388W WO2006065975A3 WO 2006065975 A3 WO2006065975 A3 WO 2006065975A3 US 2005045388 W US2005045388 W US 2005045388W WO 2006065975 A3 WO2006065975 A3 WO 2006065975A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- necrosis factor
- tumor necrosis
- human tumor
- ankylosing spondylitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/792,734 US20090041762A1 (en) | 2004-12-13 | 2005-12-13 | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
US12/885,406 US20110195063A1 (en) | 2000-08-07 | 2010-09-17 | Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/010,954 | 2004-12-13 | ||
US11/010,954 US20050249735A1 (en) | 2000-08-07 | 2004-12-13 | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/010,954 Continuation US20050249735A1 (en) | 2000-08-07 | 2004-12-13 | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/885,406 Continuation US20110195063A1 (en) | 2000-08-07 | 2010-09-17 | Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor |
Publications (4)
Publication Number | Publication Date |
---|---|
WO2006065975A2 WO2006065975A2 (en) | 2006-06-22 |
WO2006065975A3 true WO2006065975A3 (en) | 2006-08-31 |
WO2006065975B1 WO2006065975B1 (en) | 2006-10-19 |
WO2006065975A8 WO2006065975A8 (en) | 2007-02-08 |
Family
ID=36341362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/045388 WO2006065975A2 (en) | 2000-08-07 | 2005-12-13 | Methods of treating ankylosing spondylitis using anti-tnf antibodies and peptides of human tumor necrosis factor |
Country Status (2)
Country | Link |
---|---|
US (2) | US20050249735A1 (en) |
WO (1) | WO2006065975A2 (en) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
TR199801532T2 (en) | 1996-02-09 | 1998-11-23 | Basf Aktiengesellschaft | Human antibodies that bind human TNFalpha. |
US7115557B2 (en) | 1998-09-25 | 2006-10-03 | Sciaticon Ab | Use of certain drugs for treating nerve root injury |
SE9803710L (en) * | 1998-09-25 | 2000-03-26 | A & Science Invest Ab | Use of certain substances for the treatment of nerve root damage |
US7811990B2 (en) * | 1998-09-25 | 2010-10-12 | Sciaticon Ab | Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus |
US7906481B2 (en) * | 1998-09-25 | 2011-03-15 | Sciaticon Ab | Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus |
US20110195063A1 (en) * | 2000-08-07 | 2011-08-11 | Centocor, Inc. | Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor |
CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
KR20140058649A (en) * | 2002-07-19 | 2014-05-14 | 애브비 바이오테크놀로지 리미티드 | TREATMENT OF TNFα RELATED DISORDERS |
TWI439284B (en) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | Multiple-variable dose regimen for treating tnfα-related disorders |
US20060083741A1 (en) * | 2004-10-08 | 2006-04-20 | Hoffman Rebecca S | Treatment of respiratory syncytial virus (RSV) infection |
CA2903138A1 (en) | 2005-05-16 | 2006-11-23 | Abbvie Biotechnology Ltd. | Use of tnfa inhibitor for treatment of erosive polyarthritis |
US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
AU2006337105B2 (en) * | 2005-11-01 | 2013-05-02 | Abbvie Biotechnology Ltd | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
KR20150006085A (en) | 2006-04-05 | 2015-01-15 | 애브비 바이오테크놀로지 리미티드 | Antibody purification |
WO2007120656A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
EP2703010A3 (en) * | 2006-04-10 | 2014-08-06 | AbbVie Biotechnology Ltd | Uses and compositions for treatment of rheumatoid arthritis |
US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
CA2651992A1 (en) | 2006-06-30 | 2008-01-10 | Abbott Biotechnology Ltd. | Automatic injection device |
CA2692428A1 (en) * | 2006-07-07 | 2008-01-10 | James R. Gorman | Methods for preventing, postponing or improving the outcome of invasive spinal procedures |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
CA2910619A1 (en) | 2006-09-13 | 2008-03-20 | Abbvie Inc. | Cell culture improvements |
CN101616932A (en) | 2006-10-27 | 2009-12-30 | 艾博特生物技术有限公司 | Crystalline anti-hTNFalpha antibodies |
US8142388B2 (en) * | 2006-10-30 | 2012-03-27 | Gomez Mario P | Apparatus to facilitate removal of cataracts of from the eyes |
US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
US8753839B2 (en) | 2007-08-08 | 2014-06-17 | Abbvie Inc. | Compositions and methods for crystallizing antibodies |
JP6078217B2 (en) | 2008-01-15 | 2017-02-08 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | Powdered protein composition and method for producing the same |
US20110262456A1 (en) * | 2008-11-14 | 2011-10-27 | Rekha Bansal | Method of treating ischemia reperfusion injury |
CN102336834B (en) * | 2010-07-22 | 2014-01-01 | 苏州工业园区晨健抗体组药物开发有限公司 | Fully human TNFalpha-Fab antibody and its PEG antibody |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
AU2013309506A1 (en) | 2012-09-02 | 2015-03-12 | Abbvie Inc. | Methods to control protein heterogeneity |
CN104870474B (en) | 2012-10-04 | 2019-03-12 | 诺沃姆德治疗公司 | For treating the alternative pathway specific antibody of hemolytic disease |
CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
US10460024B2 (en) * | 2016-01-05 | 2019-10-29 | Adobe Inc. | Interactive electronic form workflow assistant that guides interactions with electronic forms in a conversational manner |
JP2019529541A (en) | 2016-09-08 | 2019-10-17 | エマーゴ セラピューティクス,インク. | Mast cell stabilizer for the treatment of hypercytokinemia and viral infection |
EP3528809A4 (en) | 2016-10-18 | 2020-06-10 | Emergo Therapeutics, Inc. | Mast cell stabilizers for treatment of chronic inflammatory conditions |
GB201701404D0 (en) * | 2017-01-27 | 2017-03-15 | Micropharm Ltd | Therapies for treating inflammatory disorders |
KR20190024572A (en) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | Subcutaneous Dose Regimen For Treating TNFα-related Disorders |
WO2021062372A1 (en) | 2019-09-26 | 2021-04-01 | Amgen Inc. | Methods of producing antibody compositions |
JP2023548767A (en) | 2020-10-15 | 2023-11-21 | アムジエン・インコーポレーテツド | Relative unpaired glycans in antibody production methods |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004050683A2 (en) * | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
US20040138427A1 (en) * | 1991-03-18 | 2004-07-15 | Centocor, Inc. | Anti-TNF antibodies and peptides of human tumor necrosis factor |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603106A (en) * | 1982-02-22 | 1986-07-29 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
US4822776A (en) * | 1981-09-08 | 1989-04-18 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
US6309640B1 (en) * | 1981-09-08 | 2001-10-30 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
US6419927B1 (en) * | 1981-09-08 | 2002-07-16 | Anthony Cerami | Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3631229A1 (en) * | 1986-09-13 | 1988-03-24 | Basf Ag | MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE |
EP0288088B1 (en) * | 1987-04-24 | 1994-03-09 | Teijin Limited | Detection of tumor necrosis factor; monoclonal antibody and kit |
US5360716A (en) * | 1988-10-24 | 1994-11-01 | Otsuka Pharmaceutical Co., Ltd. | Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α |
US5223395A (en) * | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
US5342613A (en) * | 1988-12-27 | 1994-08-30 | Health Research Inc. | Pharmaceutical compositions and use thereof in the treatment of psoriasis |
US5959087A (en) * | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
US5958413A (en) * | 1990-11-01 | 1999-09-28 | Celltech Limited | Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor |
GB9028123D0 (en) * | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US6284471B1 (en) * | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
MX9204374A (en) * | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION. |
WO1994008619A1 (en) * | 1992-10-08 | 1994-04-28 | The Kennedy Institute Of Rheumatology | Treatment of autoimmune and inflammatory disorders |
JPH08509203A (en) * | 1992-10-15 | 1996-10-01 | ダナ−ファーバー キャンサー インステテュート インコーポレイテッド | Treatment of obesity-related diabetes type II insulin resistance with antagonists of TNF-α action |
GB9225448D0 (en) * | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
ATE204299T1 (en) * | 1993-03-05 | 2001-09-15 | Bayer Ag | HUMAN MONOCLONAL ANTI-TNF ALPHA ANTIBODIES |
SE9302490D0 (en) * | 1993-07-26 | 1993-07-26 | Kabi Pharmacia Ab | NEW USE OF OLD DRUGS |
GB9403909D0 (en) * | 1994-03-01 | 1994-04-20 | Erba Carlo Spa | Ureido derivatives of naphthalenephosphonic acids and process for their preparation |
US6190691B1 (en) * | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
FR2728793A1 (en) * | 1994-12-28 | 1996-07-05 | Oreal | Compsns. for treating sensitive skin |
GB9702088D0 (en) * | 1997-01-31 | 1997-03-19 | Pharmacia & Upjohn Spa | Matrix metalloproteinase inhibitors |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
-
2004
- 2004-12-13 US US11/010,954 patent/US20050249735A1/en not_active Abandoned
-
2005
- 2005-12-13 WO PCT/US2005/045388 patent/WO2006065975A2/en active Application Filing
-
2007
- 2007-03-02 US US11/713,534 patent/US20080025976A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040138427A1 (en) * | 1991-03-18 | 2004-07-15 | Centocor, Inc. | Anti-TNF antibodies and peptides of human tumor necrosis factor |
WO2004050683A2 (en) * | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
Non-Patent Citations (4)
Title |
---|
BRAUN J ET AL: "Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 359, no. 9313, 6 April 2002 (2002-04-06), pages 1187 - 1193, XP004792056, ISSN: 0140-6736 * |
GREEN L L ET AL: "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chains YACs", NATURE GENETICS, NEW YORK, NY, US, vol. 7, no. 1, May 1994 (1994-05-01), pages 13 - 21, XP000953045, ISSN: 1061-4036 * |
ST CLAIR E W: "Infliximab treatment for rheumatic disease: clinical and radiological efficacy.", ANNALS OF THE RHEUMATIC DISEASES. NOV 2002, vol. 61 Suppl 2, November 2002 (2002-11-01), pages ii67 - ii69, XP002382245, ISSN: 0003-4967 * |
TOUSSIROT E ET AL: "Recent progress in ankylosing spondylitis treatment", EXPERT OPINION ON PHARMACOTHERAPY, ASHLEY, LONDON, GB, vol. 4, no. 1, January 2003 (2003-01-01), pages 1 - 12, XP008019238, ISSN: 1465-6566 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006065975B1 (en) | 2006-10-19 |
WO2006065975A2 (en) | 2006-06-22 |
WO2006065975A8 (en) | 2007-02-08 |
US20050249735A1 (en) | 2005-11-10 |
US20080025976A1 (en) | 2008-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006065975A3 (en) | Methods of treating ankylosing spondylitis using anti-tnf antibodies and peptides of human tumor necrosis factor | |
ES2156859T3 (en) | SPECIFIC MONOCLONAL AND CHEMICAL ANTIBODIES FOR THE HUMAN TUMOR NECROSIS FACTOR. | |
WO2005012493A3 (en) | Anti-cd19 antibodies | |
WO2004001381A8 (en) | Novel raag10 cell surface target and a family of antibodies recognizing that target | |
TW200635944A (en) | Compositions and methods relating to anti-IGF-1 receptor antibodies | |
WO2006084092A3 (en) | Antibodies to oncostatin m receptor | |
EP2559705A3 (en) | Anti-activin a antibodies and uses thereof | |
WO2005112564A3 (en) | Germline and sequence variants of humanized antibodies and methods of making and using them | |
JP2007536932A5 (en) | ||
WO2006084078A3 (en) | Jam-3 and antibodies that bind thereto | |
WO2006083852A3 (en) | Luca2 and antibodies that bind thereto | |
EP1790663A4 (en) | Monoclonal antibody(ad5-10) against tumor necrosis factor-related apoptosis-inducing ligand receptor dr5, the producing method and uses thereof | |
WO2006076584A3 (en) | Kid31 and antibodies that bind thereto | |
SG146644A1 (en) | Kid3 and kid3 antibodies that bind thereto | |
MXPA05008794A (en) | Glycorpotein antigen sima135 expressed in metastatic human tumor cells. | |
WO2007144046A3 (en) | Agent for the treatment of malignant diseases | |
WO2002074251A3 (en) | Monoclonal antibody therapy for pancreas cancer | |
WO2003086456A3 (en) | Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer | |
WO2005049651A3 (en) | Cancer diagnosis and therapy | |
WO2002099062A3 (en) | Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use | |
WO2005060368A3 (en) | Humanized anti-ccr2 antibodies and methods of use | |
WO2002090504A3 (en) | Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use | |
WO2003059256A3 (en) | Genes overexpresses by ovarian cancer and their use in developing novel therapeutics especially antibodies | |
WO2002028873A8 (en) | Transcription factor polynucleotides, polypeptides, antibodies, and methods based thereon | |
EP1390057A4 (en) | Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05854159 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11792734 Country of ref document: US |